Targeting DORIS Remission and LLDAS in SLE: A Review-Reference-Cited by-同舟云学术

Targeting DORIS Remission and LLDAS in SLE: A Review

Published:2023-10-05 Issue:6 Volume:10 Page:1459-1477
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Parra Sánchez Agner R.^ORCID,van Vollenhoven Ronald F.,Morand Eric F.,Bruce Ian N.,Kandane-Rathnayake Rangi,Weiss Gudrun,Tummala Raj,Al-Mossawi Hussein,Sorrentino Alessandro

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s40744-023-00601-w.pdf

Reference62 articles.

1. Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford). 2009;48:673–5.

2. Gomez A, Qiu V, Cederlund A, et al. Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus. Front Med. 2021;8: 651249.

3. Lee YH, Choi S, Ji J, Song G. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016;25:727–34.

4. Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther. 2015;17:183.

5. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–45.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Usefulness in daily practice of the Systemic Lupus Erythematosus Disease Activity Index 2000 scale and the Systemic Lupus Erythematosus Disease Activity Score index for assessing the activity of systemic lupus erythematosus;Rheumatology;2024-07-12

2. Low Disease Activity Early in the Course of Systemic Lupus Erythematosus;The Journal of Rheumatology;2024-06-15

3. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study;Frontiers in Immunology;2024-06-14

4. Correction: Targeting DORIS Remission and LLDAS in SLE: A Review;Rheumatology and Therapy;2024-06-07

5. Initiation of belimumab with higher daily prednisolone is effective for rapid glucocorticoid reduction: A 96-week retrospective study;Lupus;2024-03-21